ANI Pharmaceuticals Reports Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
ANI Pharma (ANIP) Tops Q2 EPS by 16c, Updates Guidance
August 7, 2019 8:34 AM EDTANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.44, $0.16 better than the analyst estimate of $1.28. Revenue for the quarter came in at $54.4 million versus the consensus estimate of $55.2 million.
GUIDANCE:
ANI Pharma sees FY2019 EPS of $5.57-$6.21, versus the consensus... More



